Training the antiviral drug developers of the future

Viral infections are a major course of disease worldwide. Licensed antiviral drugs are currently only available for a few viruses, such as HIV, influenza and hepatitis C. Through a multi-disciplinary, inter-sectoral training programme, the ANTIVIRALS project is training a new generation of experts to develop novel antiviral drugs

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czechia
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czechia
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia


 

Published: 10 January 2017  
Related theme(s) and subtheme(s)
Health & life sciences
Research policyHorizon 2020
Special CollectionsHepatitis
Countries involved in the project described in the article
Austria  |  Belgium  |  France  |  Germany  |  Luxembourg  |  Netherlands  |  United Kingdom
Add to PDF "basket"

Training the antiviral drug developers of the future

Picture of the tablespoons full of drugs

© hin255 - fotolia.com

Antiviral drug developers of the future require expertise in molecular virology, biochemistry, structural biology, computer-aided drug design and medicinal chemistry. Few, if any European universities or research institutes have the broad know-how needed to offer such a comprehensive training programme. The result is a lack of scientists qualified to take antiviral drug development further.

ANTIVIRALS is providing early stage researchers with state-of-the-art scientific and technological knowledge in each of relevant disciplines through network-wide training courses and workshops. Expertise will be further developed during individual research projects, which will address viruses such as enteroviruses, dengue, chikungunya and the respiratory syncytial virus, and will be partly carried out outside of the researcher’s host university.

The network also includes five industrial partners, ensuring that the 15 recruits experience the private sector as well as academia. The companies will help each individual to develop an idea from their own research project for commercialisation.

In addition to the training, the ANTIVIRALS project also has ambitious research objectives: to identify, design and characterise novel inhibitors for six virus types, and to develop them into lead candidates for antiviral therapy.

Project details

  • Project acronym: ANTIVIRALS
  • Participants: Netherlands (Coordinator), Germany, UK, France, Belgium, Austria, Luxembourg
  • Project N°: 642434
  • Total costs: € 3 849 087
  • EU contribution: € 3 849 087
  • Duration: March 2015 – February 2019

See also

 

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project website
Project details